NCT04447469Phase 2, phase 3Completed

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Study sponsor: Kiniksa Pharmaceuticals International, plc · KNSA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-11-12Actual
Enrollment · participants814Actual
Source updated2025-01-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview